Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

The STAMP RSV Program

STAMP-RSV is guided by a community reference group with lived experiences of RSV. The goal is to translate research findings into effective and efficient RSV control policies to reduce the health and economic burden of RSV.

 

Investigators

  • Chief Investigator A/Prof Hannah Moore, The Kids Research Institute Australia, hannah.moore@telethonkids.org.au
  • Prof Christopher Blyth, Perth Childrens Hospital & The Kids Research Institute Australia
  • Dr Samantha Carlson, The Kids Research Institute Australia
  • Fiona Giannini, The Kids Research Institute Australia
  • Dr Minda Sarna, The Kids Research Institute Australia
  • Dr David Foley, PathWest, Genomics
  • Catherine Hughes, Immunisation Foundation of Australia
  • Prof Peter Richmond, Perth Childrens Hospital
  • Dr Avram Levy, PathWest, Genomics
  • A/Prof Ewan Cameron, The Kids Research Institute Australia

Project Description

STAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of emerging RSV immunisation strategies by providing the evidence to inform public health policy.  

This project is focused on 4 key interrelated aims, each aim includes specific objectives and uses wide-ranging methodologies, drawing on the expertise of the multidisciplinary investigator team.

  • Aim 1 – Raising Community Awareness
  • Aim 2 – Enhancing Surveillance
  • Aim 3 – Population Dynamics
  • Aim 4 – Public Health Impact

The overarching methodology is epidemiological data analysis of real-world data, taking advantage of WA’s unique data resources and meaningful connections with stakeholders in the research, community and health services sector.

STAMP-RSV is guided by a community reference group with lived experiences of RSV. The goal is to translate research findings into effective and efficient RSV control policies to reduce the health and economic burden of RSV. We will create a respiratory infection platform that can be adapted for other viruses (e.g, parainfluenza, human metapneumovirus) likely to be on vaccine development pathways.

Funders

Stan Perron Charitable Foundation